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1. ABSTRACT
The aim of the present work was to minimize or prevent the degradation of rifampicin,
the antitubercular drug in gastric pH condition to improve the stability and therapeutic
efficacy of the drug. The study was carried out by preparing Rifampicin loaded PLGA
nanoparticles  using  ascorbic  acid  as  an  antioxidant.  Dug  loaded  nanoparticles  were
fabricated  by  a  multistep  emulsion  procedure  and  evaluations  of  the  prepared
nanoparticles  were  then  carried  out  by  various  methods.  In  this  study  four  types  of
formulations  were  prepared.  Formulation  1  (F1)  is  rifampicin  alone  loaded  PLGA
nanoparticles,  formulation  II  (F2)  is  rifampicin  –  ascorbic  acid  (1:1)  loaded  PLGA
nanoparticles,  formulation  III  (F3)  is  rifampicin  -  ascorbic  acid  (1:2)  loaded  PLGA
nanoparticles and formulation IV (F4) is rifampicin – ascorbic acid (1:3) loaded PLGA
nanoparticles. The study concluded that ascorbic acid can minimize the degradation of
rifampicin in acidic pH condition and thus improves the stability and bioavailability of
rifampicin. The results also demonstrate that there is a statistically significant change in
the percentage  drug degradation  profile  when  the concentration  of  ascorbic  acid  was
increased.
1
 INTRODUCTION
Tuberculosis  TB  is  a  ubiquitous,  high  contagious  chronic  granulomatous  bacterial
infection caused by the Mycobacterium tuberculosis. Tuberculosis affects one third of the
world population, i.e. nearly 2 billion individuals, also responsible for 3 million death
annually. India accounts for 20% of all new TB cases in the world each year .1               
 The anti-TB drugs are mainly categorized into two types namely, first line and second
line  drugs.  First  line  drugs  include  Rifampicin  (RIF),  Isoniazid  (INH),  Pyrazinamide
(PYZ),  Ethambutol  (ETB)  and  Streptomycin  and  second  line  drugs  include
Ciprofloxacin,  Levofloxacin,  Ofloxacin,  Saprofloxacin,  Capreomycin,  Anamycin,
Ethionamide, Para-amino salicylic acid, Cyclosporine and Thiacteazone.
Because of the need to take anti tubercular drugs (ATDs) daily or several times a week,
there may be chance for patient noncompliance and this result in treatment failure as well
as the emergence of drug resistance. Patient compliance can be improved by the use of
ATD formulations which reduce the dosing frequency of the drugs. The World Health
Organization (WHO) and International  Union against  Tuberculosis  and Lung Disease
(IUATLD)  recommended  the  use  of  four  drug  fixed  dose  combination  (FDC)  to
overcome these problems. The first-line drugs used in the treatment of TB are shown to
have excellent  potency against  M. Tuberculosis.  Among the four drugs,  rifampicin is
known to be the most unstable and recent studies have shown that this drug particularly
undergoes rapid degradation in the presence of Isoniazid. 
Rifampicin  is  a  semi  synthetic  macrocyclic  antibiotic  derived  from  streptomyces
mediterranei  which  has  a  unique  role  in  killing  the  semi-dormant  tubercle  bacilli.
Rifampicin acts by inhibiting mycobacterial DNA-dependent RNA polymerase synthesis
by blocking RNA transcription. It is also known to have cytochrome P450 activity.2 RIF
can be hydrolyzed to even less soluble form such as 1-amino-4-methyl piperazine under
acid gastric conditions. At pH-values between 7.4 and 8.2, the molecule is oxidized to an
insoluble quinone derivative or a desacetylated form. The major degradation products of
rifampicin are  3-formylrifamycin,  rifampicin  N-oxide,  25-desacetyl  rifampicin  and
rifampicin quinine.3
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Small molecular weight antioxidants like Vitamin C and Vitamin E plays an important
role in protecting the human tissues from oxidative damage by a variety of mechanisms.
Vitamin  C  supplements  have  been  shown to  alter  many different  indexes  of  human
immune responses and the concentration of vitamin C is high in activated neutrophils and
macrophages.  Therefore  Vitamin  supplementation  may  prove  to  be  beneficial.4
.Rifampicin is well absorbed in the pH range of 1-2 even though it undergoes degradation
in the acidic medium. To prevent this degradation Vitamin C can be incorporated into
rifampicin-PLGA nanoparticles as an antioxidant to increase the stability of rifampicin.
 For a drug molecule to reach the target site from the site of administration in sufficient
concentration and to maintain therapeutic levels for a sufficient period of time, a delivery
system  is  needed.  Among  the  various  colloidal  drug  delivery  systems  available,
nanoparticles  represent  a  very  promising  approach  to  this  aim.  Nanoparticles  are
desirable for drug delivery because of number of properties. They are known to cross the
intestinal  permeability  barriers  directly  via  transcellular/paracellular  pathways,  which
explain  better  delivery  of  the  encapsulated  drug  into  the  circulation.5.  In  this  case,
nanoparticles  are  expected  to  penetrate  inside  the  infected  cell  where  TB  is  an
intracellular infection.
Among the various polymers used in drug delivery research, PLGA (poly-d,l-lactide-co-
glycolide)  is  one  of  the  most  successfully  used  biodegradable  nanosystem  for  the
development of nanomedicines since it undergoes hydrolysis in the body to produce the
biodegradable metabolite monomers, lactic acid and glycolic acid. Since the body can
effectively  deal  with  these  two  monomers,  there  is  very  minimal  systemic  toxicity
associated with this polymer.
Thus the purpose of the present study was to prepare and evaluate  Rifampicin  loaded  
PLGA nanoparticles and an attempt was made to investigate the influence of ascorbic 
acid as an antioxidant on stabilizing rifampicin in the gastric environment by In vitro 
study.
3
LITERATURE
3.  REVIEW OF LITERATURE
Tuberculosis  infection  is  caused  by  tubercle  bacilli,  which  belong  to  the  genus
Mycobacterium. These form a large group, but only three relatives are obligate parasites,
that  can  cause  tuberculosis  disease.  They are  part  of  the Mycobacterium tuberculosis
complex and include M.tuberculosis, M.bovis and M.africanum. However generally only
the first two are found in isolates from people with tuberculosis diagnosed in the U.K,
with M.tuberculosis accounting for over 98% of isolates.6
 Rifampicin  is  a  first  line  anti-tubercular  drug,  administered  orally  in  fixed  dose
combination with Isoniazid,  Pyrazinamide and Ethambutol in order  to overcome drug
resistance to tuberculosis arising from administration of these drugs separately. However
bioavailability of rifampicin is reduced owing to degradation of the drug in the stomach
which is further influenced by Isoniazid which is also delivered in the stomach from fixed
dose combination. 
The application of microsphere technology to the treatment of the initial infection with
M. tuberculosis has been studied so that multiple-drug-resistant strains do not develop.
Modern  drug  carrier  systems  play  an  important  role  in  controlled  delivery  of  a
pharmaceutical  agent  to the target  at  a therapeutically optimal rate  and dose.  Among
various colloidal drug delivery systems, nanoparticles(NPs) represent a very promising
approach to this aim .NPs may be defined as being submicronic colloidal systems; once
in the bloodstream, surface-nonmodified NPs (conventional NPs) are rapidly opsonized
and  massively  cleared  by  the  fixed  macrophages  of  mononuclear  phagocyte  system
organs such as liver, lungs, and spleen.7 
To  understand  in  detail  the  scope  for  improving  the stability  of  anti  tubercular  drug
rifampicin,  by  the  addition  of  ascorbic  acid  a  detailed  review  of  etiology  and
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epidemiology of tuberculosis, diagnosis of the disease, drug therapy in tuberculosis, new
TB  drugs  in  development,  bioavailability  of  rifampicin  from  different  routes  of
administration, degradation of rifampicin and methods attempted to prevent degradation
is presented.
3.1. ETIOLOGY OF TUBERCULOSIS
Infection with  tubercle  bacilli  occurs  in the vast  majority  of cases  by the  respiratory
route. The lung lesions caused by infection commonly heal, leaving no residual changes
except occasional pulmonary or tracheobronchial lymph node calcification. Over 90% of
people initially infected enter this latent  phase,  from which there is a lifelong risk of
reactivation. In approximately 5-10% of apparently normal hosts and as many as 50% of
people with  advanced  HIV infection,  the initial  infection  may progress  to  pulmonary
tuberculosis or , by lymphohaematogenous spread of bacilli , to pulmonary, meningeal or
other extra pulmonary involvement ,or lead to disseminated disease (miliary TB).
Pulmonary (respiratory) TB is more common than extra pulmonary (non-respiratory) TB.
Sites of extra pulmonary TB can include the pleura, lymph nodes, pericardium, kidneys, 
meninges, bones and joints, larynx, skin, intestine, peritoneum and eyes.
Symptoms include fatigue, fever, night sweats, and weight loss, which may occur early,
while localizing symptoms of cough,  chest  pain,  haemoptysis  and hoarseness become
prominent in the advanced stages.6
3.2. EPIDEMIOLOGY OF TUBERCULOSIS
Tuberculosis has afflicted the human race for  centuries. The estimated annual risk of
tuberculosis infection and its highest prevalence are in sub-Saharan Africa and Southeast
Asia. In many industrialized countries, TB has recently failed to decline, and in Eastern
Europe and the former Soviet Union, cases and deaths are increasing. Drug resistance is a
serious problem, especially in the United States.8
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In  countries where the incidence of tuberculosis is stable and HIV-1 absent, a control
programme reaches the WHO targets of 70% case detection and 85% cure, would reduce
the incidence rate by 11% (range 8-12) per year and the death rate by 12% (9-13) per
year. Without greater effort to control tuberculosis, the annual incidence of the disease is
expected to increase by 41% (21-61) between 1998 and 2020 (from 7.4 million to 10.6
million cases per year). Achievement of WHO targets by 2010 would prevent 23% (15-
30) or 48 million cases by 2020.10.The average prevalence of all forms of tuberculosis in
India is estimated to be 5.05 per thousand, prevalence of smear-positive cases 2.27 per
thousand  and  average  annual  incidence  of  smear-positive  cases  at  84  per  1,00,000
annually.9
TB remains a major cause of morbidity and mortality worldwide in the 21st Century. The
WHO and other organizations have put vast resources into studying the disease, as well
as implementing and monitoring treatment. There are large disparities between the rates
of TB in children in resource poor countries and those in industrialized countries. Factors
such  as  poverty,  overcrowding  and  HIV  infection  have  contributed  greatly  to  the
resurgence of childhood TB, particularly in Sub-Saharan Africa. The mortality rates from
TB in children from resource-poor counties are unacceptably high. While there are many
challenges  in  the  diagnosis  and  treatment  of  TB  in  children,  perhaps  the  greatest
challenge globally is to begin to identify the extent of disease in this forgotten group.10.
 Global  incidence  and  prevalence:-   WHO estimates  that  approximately  one  third  of
global community is infected with TB. In 2000 an estimated 2-9 million incident cases
and approximately 3 million deaths are occurred worldwide due to TB. After AIDS, TB
is the second most common cause of death and current trends suggest that TB will still be
among 10 leading causes of global disease burden in the year of 2020.
The global distribution of TB cases is skewed heavily toward low-income and emerging
economies. The highest prevalence of cases is in Asia, where China, India, Bangladesh,
Indonesia, and Pakistan collectively make up over 50% of the global burden. TB cases
occur predominantly (approximately 6million of the 8 million) in the economically most
6
productive 15-49 year  old age  group.  About 1.7  million people died of  TB in  2004,
including 264000 patients who are co-infected with HIV.11
Effective  control  of  tuberculosis  (TB)  requires  an  understanding  of  the  changing
epidemiology of the disease.  The success in reducing the tuberculosis  burden reflects
several factors, including improved public health efforts, physician and patient education,
infection  control  measures,  and  the  use  of  directly  observed  therapy  (DOT).  Future
efforts to curtail the incidence of TB will require vigilant public health efforts, improving
education of patients and health care personnel,  identifying mechanisms and routes of
transmission, and assuring adequate treatment and prophylactic regimens among infected
individuals.12
3.3. DIAGNOSIS
The preliminary diagnosis of tuberculosis disease is based on the symptoms and signs in
the patient,  in  conjugation with  skin tests,  chest  X-rays,  sputum analysis  (smear  and
culture)  and  PCR  test  to  detect  the  genetic  material  of  the  causative  bacteria.
Microbiological investigations can confirm the diagnosis, although this can take up to 6
weeks using routinely available techniques.6
3.4. DRUG THERAPY IN TUBERCULOSIS
Current anti-tuberculosis chemotherapy
Since the control measures for TB such as Bacillus Chalmette- Guerin (BCG) vaccination
and chemoprophylaxis appear to be unsatisfactory,  treatment with anti-tubercular (anti-
TB) drugs becomes the only option available. The goals of treatment are to ensure cure
without relapse, to prevent death, to impede transmission, and to prevent the emergence
of  drug  resistance.  Long  term  treatment  with  a  combination  of  drugs  is  required.
Treatment of active TB with a single drug should never be attempted, and a single drug
should never be added to a failing regimen, the result being development of MDR TB.
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As suggested by WHO, treatment of TB and drug resistant cases require multi-drug 
therapy, comprising:
1. An initial intensive phase of rifampicin (RIF), Isoniazid (INH), Pyrazinamide (PYZ), 
and Ethambutol (ETB) daily for 2 months.
2. A continuation phase of RIF and INH for a further 4 months, either daily or 3 times per
week, to be administered.
INH eradicates most of the rapidly replicating bacilli in the first 2 weeks of treatment,
together with streptomycin and ETB. Thereafter, RIF and PYZ have an important role in
the  sterilization  of  lesions  by  eradicating  organisms;  these  two drugs  are  crucial  for
successful 6-month treatment regimens. RIF kills low or non-replicating organisms and
the high sterilizing effect of PYZ serves to act on semi dormant bacilli not affected by
any other anti-TB agents in sites hostile to the penetration and action of the other drugs.
INH and RIF, the two most potent anti-TB drugs, kill more than 99% of tubercular bacilli
within 2 months of initiation of therapy. Using these drugs in conjunction with each other
reduces anti-TB therapy from 18 months to 6 months.                       
 Tuberculosis  treated  with  a  multi-drug  regimen,  is  thus  exceptionally  vulnerable  to
incidences of side effects,  unsatisfactory patient compliance and slow improvement of
patients. Therefore, despite the availability of these highly effective treatments for TB,
cure  rates  remain  low,  as  commercial  anti-TB  formulations  are  inconvenient  to
administer and patients do not take the prescribed medications with sufficient regularity
and duration to achieve a cure . 
Patients have to consume a large number of tablets (up to eight at one time), which is a
common cause for non-compliance. It can be anticipated that non-optimal application of
these short course regimens will result in the deterioration of their therapeutic potential,
an  escalation  in  the  mortality  rate  and  increased  risk  of  developing  acquired  drug
resistance. Resistance of  M. tuberculosis  to anti-TB agents is a worldwide problem in
both Immuno competent and HIV-infected populations.13
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3.5. NOVEL DRUG DELIVERY SYSTEMS FOR THE TREATMENT OF 
TUBERCULOSIS
Chemotherapy of TB is complicated by the need of multidrug regimens that need to be
administered  over  long  periods.  Poor  patient  compliance  is  the  single  most  common
reason  for  chemotherapy  failure  in  TB.  To  minimize  toxicity  and  improve  patients'
compliance, extensive progressive efforts have been made to develop various implant-,
micro particulate-, and various other carrier- based drug delivery systems to either target
the site of  M. tuberculosis  infection or reduce the dosing frequency,  which forms an
important therapeutic strategy to improve patient outcomes.
Recent  trends  in  controlled  drug  delivery  have  seen  microencapsulation  of
pharmaceutical  substances  in  biodegradable  polymers  as  an  emerging  technology.
Carriers or delivery systems such as liposomes and microspheres have been developed
for  the  sustained  delivery  of  anti-TB  drugs  and  have  demonstrated  better
chemotherapeutic efficacy when investigated in animal models (e.g. mice).Anti-TB drugs
have been successfully entrapped and delivered in biodegradable polymers such as poly
(DL-lactide-  co-glycolide)  (PLG),  which  are  biocompatible  and  release  drug  in  a
controlled manner at therapeutic levels. Amidst these concerns, Ain et al. reported the
pharmacokinetics  of  PLG  encapsulated  anti-TB  drugs;  orally  administered  either
individually or in combination in mice. A study conducted by Pandey et al. reported the
formulation of three frontline anti-TB drugs, i.e. RIF, INH and PYZ encapsulated in PLG
nanoparticles.  On oral  administration of drug-loaded nanoparticles to  M. tuberculosis-
infected mice at every 10th day, no tubercle bacilli could be detected in the tissues after 5
oral doses of treatment. 
Therefore,  oral  nanoparticle-based  anti-TB drug therapy can  allow for  a  reduction  in
dosing  frequency  for  better  management  of  TB.  Prabakaran  et.al  developed  an
osmotically regulated capsular multi-drug oral delivery system comprising asymmetric
membrane coating- and dense semi permeable membrane coating-capsular systems for
the simultaneous controlled administration of RIF and INH for the treatment of TB. This
was  in  an  attempt  to  reduce  the  problems  associated  with  multidrug  therapy.  The
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modified  asymmetric  system provided satisfactory sustained release  of  RIF and INH,
with  an  initial  burst  release  that  may  be  sufficient  to  achieve  minimum  effective
concentration in blood. Thereafter, the system provided the release of the drugs in a near
zero order rate – an ideal release profile for controlled drug delivery. In turn, this would
improve  the  safety  profile  of  the  drugs  and  enhance  the  activity  duration  of  drugs
exhibiting  short  half-lives.  The  once  daily  system  is  optimal,  and  could  potentially
enhance patient compliance.
In addition to these combinations, the past several years have seen the development of a
number of RIF-only controlled release formulations for the improvement of the clinical
efficacy  of  the  drug  and  patient  compliance.  Further  attempts  to  solve  the  problems
inherent in multidrug therapy have included the development of biodegradable polymeric
micro- or nanoparticulate carrier systems to target alveolar macrophages that harbor  M.
tuberculosis.  In  the case of pulmonary TB, delivering the drug directly to the site of
infection  through  inhalation  of  an  aerosolized  delivery  system  has  the  inherent
advantages  of  bypassing  first-pass  metabolism  and  maintaining  local  therapeutically
effective concentrations with decreased systemic side effects. 
In another approach to solve the predicament of poor patient compliance, depot-delivery
of anti-TB drugs has been investigated. Studies have demonstrated that a single implant
of INH in polylactic-co-glycolic acid (PLGA) copolymer could ensure sustained levels of
free INH for a period of up to 8 weeks following implantation in rabbits. Gangadharam,
et al.have also investigated the chemotherapy of TB in mice using single implants of INH
and  PYZ.  Such  devices,  however,  inherently  suffer  from  the  disadvantages  of
immobilization  at  the  implantation  site  and  surgical  requirements  for  implantation.
However,  the  need  to  develop  an  oral  drug  delivery  system  with  improved  patient
acceptance is affirmed by the accelerated pace of oral drug delivery system development
fostered by the need to deliver medications to patients more efficiently and with fewer
side effects,  especially in developing countries where controlled-delivery implants and
injectable could be too expensive.13
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Particle  size,  encapsulation efficiency and the structure of the composite  particles are
important  properties  with  respect  to  pharmaceutical  application.  Size  and  structure
influence the kinetics of drug release, pharmaceutical behavior and cellular uptake of the
particles. Relationship between the particle properties and the conditions of preparation
were studied and characterized by several authors14
3.6. NANOPARTICLES AS DRUG DELIVERY SYSTEMS
Over the last few decades,  the applications of nanotechnology in medicine have been
extensively explored in many medical areas, especially in drug delivery. Nanotechnology
concerns the understanding and control of matters in the 1- 100 nm ranges, at which scale
materials have unique physicochemical properties including ultra small size, large surface
to mass ratio, high reactivity and unique interactions with biological systems. By loading
drugs  into  nanoparticles  through  physical  encapsulation,  adsorption,  or  chemical
conjugation, the pharmacokinetics and therapeutic index of the drugs can be significantly
improved in contrast to the free drug counterparts. 
Many advantages of nanoparticle-based drug delivery have been recognized, including
improved  serum solubility  of  the  drugs,  prolonging  the  systemic  circulation  lifetime,
releasing drugs at a sustained and controlled manner, preferentially delivering drugs to
the tissues and cells of interest, and concurrently delivering multiple therapeutic agents to
the same cells for combination therapy. Moreover, drug-loaded nanoparticles can enter
host cells through endocytosis and then release drug payloads to treat microbes-induced
intracellular infections. As a result, a number of nanoparticle-based drug delivery systems
have  been  approved  for  clinical  uses  to  treat  a  variety  of  diseases  and  many  other
therapeutic nanoparticle formulations are currently under various stages of clinical tests.
MECHANISM OF NANOPARTICLE - BASED ANTIMICROBIAL DRUG 
DELIVERY TO MICROORGANISMS
11
Fig. (1).  (a)  nanoparticles fuse with microbial  cell wall  or membrane and release the
carried drugs within the cell wall or membrane; (b) nanoparticles bind to cell wall and
serve as a drug depot to continuously release drug molecules, which will diffuse into the
interior of the microorganisms.15
These  nanocarriers  are  sub  micron  particles  containing  entrapped  drugs  intended  for
enteral  or  parenteral  administration  which  might  prevent  or  minimize  the  drug
degradation and metabolism as well as cellular efflux. Nanoparticles also have a long
shelf life, are made of safe materials, including synthetic biodegradable polymers, natural
biopolymers, lipids and polysaccharides and have the potential for overcoming important
mucosal barriers, such as intestinal, nasal and ocular barriers. 5
3.7 POLYMERS AS DRUG DELIVERY VEHICLE
A  number  of  polymers  have  been  investigated  for  formulating  biodegradable
nanoparticles, such as polylactide (PLA), polycaprolactone (PCL) and poly (lactide-co-
glycolide)  (PLGA).  These are biocompatible  and biodegradable polymers  which have
recently  been  the  subject  of  extensive  investigation.  However,  due  to  copolymer
crystallization,  low biodegradation rate  or  poor flexibility,  the application of  polymer
nanoparticles is limited. For example, in case of homopolymer poly (L-lactide), due to its
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crystalline and low biodegradation rate, drug release from relevant drug delivery devices
is mainly controlled by drug diffusion similar to that in non-degradable drug carriers.
Biodegradation  of  polymeric  biomaterials  involves  cleavage  of  hydrolytically  or
enzymatically sensitive bonds in a polymer, leading to polymer erosion. Depending on
the  mode  of  degradation,  polymeric  biomaterials  can  be  further  classified  into
hydrolytically degradable polymers  and enzymatically degradable polymers.  The most
part of naturally occurring polymers undergo enzymatic degradation. Biodegradation of
hydrolysable polymers proceeds in a diffuse manner, with amorphous regions degrading
prior  to  the  complete  split  of  crystalline  and  cross-linked  regions.  Factors  affecting
biodegradation  of  polymers  might  be:  chemical  structure,  chemical  composition,
distribution  of  repeat  units  in  multimers,  presence  of  ionic  groups,  presence  of
unexpected units or chain defects, configuration structure, molecular weight, molecular
weight  distribution,  morphology(amorphous/semi  crystalline,  microstructures,  residual
stresses),presence of low molecular-weight compounds, processing conditions, annealing,
sterilization process, storage history, shape, site of implantation, adsorbed and absorbed
compounds  (water,  lipids,  ions,  etc.),  physicochemical  factors  (ion  exchange,  ionic
strength  pH),  physical  factors  (shape  and  size  changes,  variations  of  diffusion
coefficients, mechanical stresses, stress-and solvent-induced cracking, etc.), mechanism
of hydrolysis (enzymes versus water).
Structure,  properties  and  applications  of  nanoparticles  are  strongly  affected  by  the
properties  of  the  polymer  used  in  their  formulation.  For  each  application,  one  must
evaluate  the  properties  of  the  system  (drug  and  particle)  and  determine  the  optimal
formulation for a given drug delivery application. Polyesters based on polylactide (PLA),
polyglycolide  (PGA),  polycaprolactone  (PCL),  and  their  copolymers  have  been
extensively employed as systems for drug delivery. PLGA and PLA have been approved
by the FDA for numerous clinical applications, such as sutures, bone plates, abdominal
mesh, and extended-release pharmaceuticals.
Biomedical uses of PLA have been reported since the 1960s. Tissue response to such
biodegradable materials is characterized by minimal localized inflammation and foreign
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body reaction that lessen with time. No toxic effects have been associated with the use of
such polymers, biodegraded via a random, non-enzymatic process into homopolymers of
lactic acid and glycolic acid, known products of cellular intermediary metabolism. PLGA
degrades through hydrolysis of its ester linkages in the presence of water. It  has been
shown  that  the time required  for  the  degradation  of  PLGA is  related  to  the  ratio  of
monomers used in its production: the higher the content of glycolide units, the lower the
time required for degradation. An exception to this rule is copolymer with 50:50 ratios of
monomers, which undergoes faster degradation (about two months) in both in vitro and
in vivo conditions. Miller  et al.  have shown that PLGA 50:50 is the fastest degrading
composition, with the degradation rate being decreased when either lactide or glycolide
content of the copolymer was increased 16
3.8. TB DRUGS IN DEVELOPMENT
OPC-67683
OPC-67683 is a nitromidazo-oxazole that is similar in structure to PA-824. It inhibits cell
wall  biosynthesis.  Otsuka  Pharmaceuticals  (Japan)  are  currently  conducting  phase  2
clinical trials. Preclinical studies in rodents and dogs suggest that OPC-67683 could be
used in HIV/AIDS as it has no effect on CYP. It may have treatment-shortening potential
as  it  synergizes  in  vitro  with  rifampicin  and  pyrazinamide.  OPC-67683  is  effective
against MDR-TB in vitro and displayed no cross-resistance to first line TB therapy.  It
also has potential to treat LTBI.17
Sudoterb LL3858
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 Limited data are available regarding pyrrole LL3858. It is currently undergoing phase 1
clinical trials by Lupin Limited (India). Available data suggest that LL3858 has potency
against standard and drug-sensitive TB strains in vitro.18
SQ-109
 SQ-109 is an ethylenediamine analogue of ethambutol. It is postulated to inhibit cell wall
biosynthesis and has intracellular targets, which have not yet  been elucidated.  SQ-109
appears to be synergistic with Isoniazid and rifampicin.19
Gatifloxacin
Gatifloxacin  is  a  fluroquinolone  that  inhibits  DNA  gyrase,  thus  inhibiting  TB  DNA
replication and transcription. Gatifloxacin is currently undergoing phase 3 clinical trials.
Gatifloxacin holds the potential to be the first TB agent to reduce pulmonary TB therapy
to four-month duration. There are weak data to support its efficacy against MDR-TB.20
R207910
 R207910 is a diarylquinoline and is also known as Compound J and TMC207. It inhibits
ATP synthesis leading to ATP depletion and pH imbalance. Where it is undergoing phase
2a clinical trials in both drug sensitive and resistant disease. Murine studies suggest that
R207910 has a good safety and tolerability profile and potent early bactericidal activity,
matching  Isoniazid.  It  had  a  synergistic  effect  with  pyrazinamide  for  MDR-TB;
R207910/H/Z  or  R207910/R/Z  combinations  were  more  effective  than
Amikacin/Z/Moxifloxacin/Ethionamide regimens.21
PA-824
PA-824 is a nitroimidazo-oxazine. It requires activation by M. tuberculosis F420 factor
and inhibits synthesis of cell wall lipids as well as protein synthesis. The TB alliance is
currently conducting phase 1 clinical trials of PA-824. Preliminary studies suggest that
PA-824 will  be  active  against  MDR-TB and  has  no  cross-resistance  with  other  anti-
tubercular drugs. Importantly, it is not metabolized by CYP and does not induce or inhibit
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CYP. It  had similar  bacteriostatic  efficacy to  rifampicin and was more efficient  than
Isoniazid or moxifloxacin but less efficient than rifampicin.22
Moxifloxacin
Moxifloxacin is a fluroquinolone and has a similar mechanism of action to Gatifloxacin.
Moxifloxacin kills rifampicin-tolerant persisters in vitro, and it may help treat MDRTB if
co-administered with Ethionamide. It may thus shorten duration of TB therapy.23
3.9. BIOAVAILABILITY OF RIFAMPICIN
 The therapeutic potential of rifampicin (RIF) in tuberculosis is well recognized due to its
unique ability to kill semi dormant tubercle bacilli (Mycobacterium tuberculosis), when
they undergo sporadic bursts of metabolism and growth 24
After oral administration on an empty stomach, the absorption of rifampicin (rifampin) is
rapid and practically complete. With a single 600mg dose ,peak serum concentration of
the order of 10microgram/ml generally occurs after 2 hours of administration. The half-
life of rifampicin for this dose level is of the order of 2.5 hours. Approximately 80% of
rifampicin  is  transported  in  blood  bound  to  plasma  proteins,  mainly  albumin.
Desacetylrifampicin, the more polar metabolic derivative of rifampicin, behaves in the
opposite way since its rate of transfer into bile is 4 times higher than that into urine. The
rate of biotransformation of rifampicin into desacetylrifampicin is of the same order of
magnitude as that of biotransformation of the latter into a further metabolic derivative,
which could be a glucuronide conjugate.25
Rifampicin is readily absorbed from the gastro- intestinal (GI) tract and showed that the
pharmacokinetic  parameters after  intravenous infusion do not differ significantly from
those after oral administration of the same doses. An absolute bioavailability of 93% after
a single oral and intravenous dose of rifampicin at the beginning of the treatment of six
adult patients decreases to fewer than 70% after repeated dosage due to self- induction of
metabolizing  enzymes  by rifampicin.  The  Cmax  after  oral  administration  of  600  mg
rifampicin averages from about 8 to 20 mg/mL. In children it can vary widely. A plasma
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protein  binding  of  80–91%  has  been  reported.  The  main  metabolic  pathway  is
deacetylation in the liver and excreted via biliary pathway. Within 24 h about 3–30% of a
single  oral  dose  is  recovered  in  the  feces.  The  antibiotic  shows  dose-dependent
elimination kinetics.26
 RIF  is  mainly  eliminated  in  the  bile  and  then  reabsorbed,  hence,  enterohepatic
circulation  ensues.  During  this  time  the  drug  is  progressively  deacylated  into  its
microbiologically  active  metabolite,  25-desacetyl  rifampicin  (DRIF)  which  is  less
absorbable  as  compared  to  the  parent  drug  24.The  formation  of  different  rifampicin
polymorphs  and the conditions for  their  inter-conversion  has been reported.  The said
publication, however, gives no data to suggest that different polymorphs of rifampicin
show different bioavailability. The assumption perhaps is based on a general premise that
different polymorphs show different bioavailability behaviour.27
The absolute bioavailability of oral  rifampin was determined in 20 pediatric  patients.
Intravenous doses of rifampin (mean 287 mg/m2) were compared with p.o. doses (mean
324 mg/m2). Pharmacokinetic analysis of the rifampin serum concentration data indicated
that only 50 +/- 22% of a freshly prepared p.o. suspension were absorbed. The rifampicin
elimination half-life following i.v. administration (2.25 +/- 0.64 h) was not different from
that  observed  following  p.o.  dose  administration  (2.61  +/-  1.35  h).  Peak  rifampin
concentrations were significantly higher following i.v. administration when corrected to a
300  mg/m2 dose  (27.4  vs.  9.1  [mu]g/ml,  respectively,  P  <  0.0001)  than  after  p.o
administration. The peak concentration following a p.o. dose occurred at 2.0 +/- 0.9 h.
The ratios of desacetylrifampicin to rifampin areas under the curves were similar for i.v.
and  p.o.  routes  of  administration  (0.23  vs.  0.19),  suggesting  linear  metabolism  of
rifampin to this metabolite. 3-formylrifamycin SV concentrations were lower than those
of desacetylrifampicin and were detectable in less than half of the patients.28
The  bioavailability  of  rifampicin  when  administered  along  with  antacids  reduces
significantly. The effect of antacids on the bioavailability of rifampicin is shown to be in
the order of magnesium trisilicate > aluminium hydroxide > sodium bicarbonate, and is
ascribed to the combined effects of gastric pH elevation, chelation of drug by aluminium
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ions and binding of rifampicin with magnesium trisilicate.29Rifampicin decomposition is
enhanced by the presence of Isoniazid in stomach after ingestion.80–90% of rifampicin
was dissolved  in  0.1 M HCl within 10 min,  and all  samples  showed an overlapping
dissolution profile.30
3.10. DEGRADATION OF RIFAMPICIN
Degradation of rifampicin in 0.1N HCl, and simulated gastric fluid (SGF) at 37°C in 45
min (USP dissolution test conditions) in the absence and presence of Isoniazid has been
documented.  Rifampicin alone decomposes  in  the described  conditions to  an average
extent of 6.33%, while the loss of rifampicin in the presence of Isoniazid increases on an
average to 16.32%.31,32
Rifampicin is well absorbed from the stomach due to its solubility, which is maximum
between pH 1-2. Isoniazid is poorly absorbed from the stomach, but is well absorbed
from all three segments of the intestine. In combination, rifampicin disappearance was
enhanced  in  the  presence  of  Isoniazid  in  the  stomach  and  jejunum,  but  Isoniazid
disappearance  was  not  influenced  by  rifampicin.  The  study  shows  higher  in  situ
rifampicin disappearance in the presence of Isoniazid,  attributable to drug degradation
due to  catalysis  by Isoniazid.  As  the two drugs  show regional  specific  permeability,
FDCs without reduced rifampicin bioavailability resulting from its decomposition in the
presence of Isoniazid can be designed by segregating delivery of the two drugs by around
3-4 h. Rifampicin should be released in the stomach and Isoniazid in the intestine.33
Rifampicin is better absorbed through the stomach and duodenum than through the distal
regions  of  the  intestine.  Rifampicin  alone  exhibited  decomposition  of  ~4% at  pH 2,
whereas it  was negligible at  pH 5.5 and 7.  Rifampicin showed similar decomposition
pattern even in the presence of Nucleotide/Nucleoside Reverse Transcriptase Inhibitors
(NRTIs).2
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3.11. METHODS ADOPTED TO MINIMIZE / PREVENT DEGRADATION OF
RIFAMPICIN
A study was carried out to determine the stability of rifampicin in plasma kept at an
ambient temperature for 24 hrs or stored at -200 C for two weeks. The possible protective
effect of adding ascorbic acid was studied in this. The results indicate that Rifampicin
degrades rapidly in plasma at ambient temperature, and 54% loss was observed within
8hrs.  This  degradation  can  be  effectively  prevented  by  adding  ascorbic  acid,  thus
prolonging the stability for up to 12hrs. Rifampicin decomposition occurs after storage
for  1  week  at  -200c.  However  in  samples  supplemented  with  ascorbic  acid  before
freezing, no degradation was observed within 14 days.34
Rifampicin oxidizes in solution to form rifampicin quinine. Ascorbic acid is often added
to solutions of RIF to slow down this oxidation and explained on short term stability
studies  in  plasma,  no degradation  was observed in  thawed samples  up to  9 hrs.  The
response after 9hr were 93.7% and 96.1% of the response at t=0hr at RIF concentrations.
Degradation was observed at lower concentration of the drug (0.5µg/ml) in the freeze
thaw samples.  However,  at  high  concentration  (20  µg/ml),  this  degradation  was  less
evident.35
Contact  between rifampicin and Isoniazid can decrease the degradation of rifampicin.
Delay  of  rifampicin  release  in  the  acidic  medium  was  achieved  by  preparing  the
Rifampicin-Sodium Lauryl  Sulphate mixture in the ratio of 1:1 by co grinding method
which is a relatively simple and effective method. Thus this approach is beneficial for the
segregation of release pattern of rifampicin in alkaline environment and Isoniazid in the
acidic  environment  of  the  GI  tract,  which  will  lead  to  prevent  the  degradation  of
rifampicin alone & its interaction with isoniazid.36
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3.12. REVIEW OF RELEVANT WORKS
Farnaz Esmaeili et al. carried out the preparation and antibacterial activity evaluation of
rifampicin-loaded poly lactide-co-glycolide nanoparticles. In this study the nanoparticles
were  prepared  by  emulsification/solvent  diffusion  method.  The  effects  of  several
variables on the nanoparticles’ characteristics were evaluated, including the amount of
rifampicin,  amount of poly vinyl  alcohol as surfactant  and internal  phase volume and
composition. The rifampicin encapsulation efficiency and the particle size distribution
were  optimized  by  varying  these  parameters.  The  nanoparticles  were  found  to  be
spherical in shape with a relatively mono dispersed size distribution. The antibacterial
activity of rifampicin against gram positive and gram negative bacteria were evaluated
and found that RIF NPs could considerably improve the RIF anti bacterial efficacy.7
Akansha  Tripathi  et  al.  prepared  and  evaluated  PLGA  nanoparticles  of  the  anti
tubercular drug, rifampicin. In this study, the nanoparticles were prepared through single
emulsion  evaporation  method.  The  rationale  of  this  study  was  to  develop  PLGA
nanoparticles loaded with rifampicin, intended to be intravenously administered and able
to improve the therapeutic index of the drug. Characterization and  invitro drug release
study of the prepared nanoparticles were also carried out. The study revealed that most of
the nanoparticles were fairly spherical in shape. The surface of the particles showed a
characteristic smoothness. The release behavior of rifampicin exhibited a biphasic pattern
characterized by an initial burst (11.26 % in 1 day)  release followed by a slower and
continuous  release  (more  than  30  days).  Therefore,  Rifampicin  loaded  PLGA
nanoparticles may be considered as an effective antitubercular drug delivery system for
therapy.1
Gambhire Vaishali et al.  carried out the  preparation and physico-chemical evaluation
of  rifampicin  loaded  poly-(lactic-co-glycolic)  acid  (PLGA)  nanoparticles  as  per  32
Factorial Design. PLGA (X1) and PVA (Polyvinyl alcohol) solution (X2) as a stabilizing
agent  were  used  as  independent  variables  where  Particle  size  (PS)  (Y1),  Entrapment
Efficiency (EE) (Y2) and % Drug Release at 12th h (REL)(Y3) were taken as dependant
variables.  In  this study the nanoparticles  were  prepared by multiple emulsion solvent
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evaporation method. The results showed the method as reproducible, easy and efficient is
the entrapment of drug as well as formation of spherical nanoparticles. Effect of polymer
concentration was also evaluated with respect to their % drug entrapment efficiency. The
in vitro release studies indicated that the rifampicin-loaded PLGA nanoparticles provide
sustained drug release over a period of 12h. The Infrared spectroscopy analysis revealed
that there was no known chemical interaction between drug and polymer.  Hence,  this
investigation demonstrated the potential of the experimental design in understanding the
effect of the formulation variables on the quality of rifampicin nanoparticles.5
Anjali Sharma et al. evaluated the chemotherapeutic efficacy of PLGA nanoparticles
encapsulating  three  front  line  anti  tubercular  drugs,  Rifampicin,  Isoniazid,  and
Pyrazinamide at sub therapeutic dose against experimental tuberculosis..In this study the
nanoparticles were prepared by double emulsion and solvent evaporation technique. A
single  oral  administration  of  the  formulation  resulted  in  sustained drug  levels  in  the
plasma for 7-12 days and in the organs for 11-14 days with a significant improvement in
mean  residence  time  as  well  as  drug  bioavailability.  The  study  concluded  that
nanoparticle based anti tubercular chemotherapy forms a sound basis for a reduction in
dosing frequency and also offers the possibility of reducing the drug dosage.37
Kunikazu Moribe et al. prepared a drug nanoparticle formulation using ascorbic acid
derivatives.  Hydrophilic ascorbic acid derivatives have been used not only as food or
pharmaceutical  excipients  but  also  as  antioxidants.  They  are  usually  loaded  into  a
nanoparticle  formulation  to  prevent  oxidation  of  the  drugs  and  the  components  .In
addition to drug solubilization, drug nanoparticle formation was observed using ascorbyl
glycoside. Hydrophobic ascorbic acid derivatives such as ascorbylmono- and di-n-alkyl
fatty acid derivatives are used either as drugs or carrier components.38
L.Zhang et al. carried out a study regarding the development of nanoparticles for anti
microbial drug delivery. The study suggested that since the nanostructured biomaterials,
particularly nanoparticles,  have unique physicochemical  properties  such as  ultra small
and  controllable  size,  large  surface  area  to  mass  ratio,  high  reactivity,  and
functionalizable structure, these properties can be applied to facilitate the administration
of  antimicrobial  drugs,  thereby  overcoming  some  of  the  limitations  in  traditional
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antimicrobial  therapeutics.  In  this,  the current  progress  and challenges in synthesizing
nanoparticle platforms for delivering various antimicrobial drugs are reviewed.15
Alejandro Sosnik et al.  carried out a study showing the various nanotechnologies that
can be applied to the treatment of tuberculosis. The study suggested that, nanotechnology
is  one  of  the  most  promising approaches  for  the development  of  more  effective  and
compliant  medicines.  This   review  thoroughly  overviews  the  state-of-the-art  in  the
development of nano-based drug delivery systems for encapsulation and release of anti-
TB drugs  and discussed  the challenges  that  are  faced  in  the development  of  a  more
effective, compliant and also affordable TB pharmacotherapy.39
Zahoor  Ahmad  et  al.  evaluated  the  chemotherapeutic  potential  of  Econazole  and
Moxifloxacin  loaded  PLGA nanoparticles  in  a  study.  In  this,  the  nanoparticles  were
evaluated against  murine TB in order  to develop a more potent regimen for TB.  The
nanoparticles were prepared by multiple emulsion and solvent evaporation method and
were  administered  orally  to  mice.  A  single  oral  dose  of  nanoparticles  resulted  in
therapeutic drug concentration in plasma for upto 5 days or 4 days whilst in the organs it
was  upto  6  days.  The  study  concluded  that  PLGA nanoparticles  appear  to  have  the
potential intermittent therapy of TB, and combination of MOX, ECZ, and RIF is the most
potent.40
Catarina Pinto Reis et al.  reviewed  the most important  preparation methods of drug
loaded polymeric nanoparticles. Advantages and disadvantages are also presented so as to
facilitate selection of an appropriate nanoencapsulation method according to a particular
application. Polymeric nanoparticles have been extensively studied as particulate carriers
in the pharmaceutical and medical fields, because they show promise as drug delivery
systems as a result of their controlled- and sustained-release properties, sub cellular size,
and biocompatibility with tissue and cells. Several methods to prepare nanoparticles have
been developed during the last two decades, classified according to whether the particle
formation  involves  a  polymerization  reaction  or  arises  from  a  macromolecule  or
preformed polymer.41
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B.N.  Vedha  Hari  et  al. thoroughly  overviewed  the  development  of  novel  micro
particulate system, encapsulation of drug, and various other carrier-based drug delivery
systems for incorporating the principal anti-TB agents.  The study discussed a detailed
description about the various nanotechnologies that can be applied to the treatment of TB
like nanosuspension, nanoemulsion, niosomes etc.42
Avnesh  Kumari  et  al. carried  out  a  study  demonstrating  the  various  biodegradable
polymeric nanoparticles based drug delivery systems. Biodegradable nanoparticles have
been used frequently as drug delivery vehicles  due to its grand  bioavailability,  better
encapsulation, control release and less toxic properties. Various nanoparticulate systems,
general  synthesis  and  encapsulation  process,  control  release  and  improvement  of
therapeutic value of nanoencapsulated drugs has been reviewed in this study. The study
highlighted  the  impact  of  nanoencapsulation  of  various  disease  related  drugs  on
biodegradable nanoparticles such as PLGA, PLA, chitosan, gelatin, polycaprolactone and
poly-alkyl-cyanoacrylates.43
Dutt  and  Khuller have  entrapped  INH  and  RIF  in  PLG  polymers.  When  injected
subcutaneously as a  single dose,  the micro particles,  having a diameter  ranging from
11.75 µm to 71.95 µm, provided sustained release of drugs over 6–7 weeks when tested
in  mice.  The  authors  previously  observed  that  particles  with  a  size  range  >10  µm
remained  at  the  site  of  injection  forming  a  depot.  The  entrapped  contents  of  the
microparticles were gradually released by diffusion through the polymeric particles. Such
depots  can  show  release  profiles  extending  over  several  months  culminating  in
degradation of the entire polymeric device. 13
Saranjith Singh et  al.  carried  out  a study to determine  the extent  of  degradation  of
rifampicin  INH and  Pyrazinamide  from prepared  mixtures  and marketed  preparations
containing single, two, three and four drugs under stomach conditions. The study was
carried out in 0.1M HCL at 37oC for 50 mints. Under these conditions, rifampicin was
decomposed by 17.8 – 24.4 %, INH to a lesser extend (3.2-4.5) and Pyrazinamide was
stable. The decomposition of rifampicin was influenced by the presence of INH and not
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by  Pyrazinamide  or  Ethambutol.  The  results  suggest  that  the  poor  bioavailability  of
rifampicin might be in part due to the decomposition of the drug in the stomach. 44
Mariappan T.T et al. carried out another study to determine the reason for an increase in
the  decomposition  of  rifampicin  in  the  presence  of  INH  under  acid  condition.  The
degradation study was performed in 0.1M HCL at 37oC in the absence and presence of
INH.  The  study  concluded  that  the  degradation  of  rifampicin  was  increased
approximately three fold in the presence of INH.45
Le  Guellec  et  al. developed  an  HPLC  assay  method  to  monitor  rifampicin  plasma
concentration that was used to study the possible degradation of rifampicin in plasma
sample.  The report  described the stability of rifampicin in plasma kept at an ambient
temperature for 24hrs or stored at - 20oc for 2 weeks. The possible protective effect of
adding ascorbic acid was also studied.  The results  indicated that  rifampicin degraded
rapidly in plasma at  an ambient temperature and a 54 % loss was observed within 8
hours.  However  in  samples  supplemented  with  ascorbic  acid  before  freezing,  no
degradation  was  observed  within  14  days  and  thus  the  authors  suggested  that
decomposition of rifampicin can be effectively prevented by adding ascorbic acid thus
prolonging the stability.46
3.13. BACKGROUND OF THE STUDY
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The  literature  survey  thus  reveals  the  importance  of  fixed  dose  combination  of
rifampicin, Isoniazid, Pyrazinamide and Ethambutol in the treatment of TB to overcome
the drug resistance and to improve the patient compliances. Rifampicin appears to be the
best  choice  for  the  treatment  of  TB  however  it  has  poor  bioavailability  from  FDC
formulation following oral administration due to degradation in the stomach. Rifampicin
is well absorbed in the pH range of 1-2 even though it undergoes  degradation in the
acidic medium and the degradation of rifampicin increases in the presence of Isoniazid
and  thus  affects  bioavailability  of  rifampicin.  Development  of  any  method  that  can
stabilize rifampicin against degradation in the stomach will be therapeutically beneficial.
Since nanoparticles are known to cross the intestinal permeability barriers directly via
transcellular /  paracellular pathways,  it  offers better delivery of the encapsulated drug
into the circulation. In this case they are expected to penetrate inside the infected cell,
where TB is an intracellular infection. From the literature study it was found that PLGA
is one of the most successfully used biodegradable nanosystem for the development of
nanomedicine since it  undergoes hydrolysis  in the body to produce the biodegradable
metabolite monomers, lactic acid and glycolic acid. Based on these considerations the
present study attempted to improve the stability of rifampicin - PLGA nanoparticles using
ascorbic acid as an antioxidant.
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                                    4. DRUG PROFILE 
4.1. Name of drug: - Rifampicin
Rifampicin is a bactericidal antibiotic drug of the rifamycin group. It is a semi synthetic
compound derived from Amycolatopsis rifamycinica (formerly known as Amycolatopsis
mediterranei and Streptomyces mediterranei). 
Structure:
          Rifampicin
Empirical formula:                      C43H58N4O12 
Molecular weight:                    822.94.
Chemical name:                3-[[(4-methyl-1-piperazinyl)imino]methyl]-   .  
                                      5,6,9,17,19,21- Hexahydroxy-23-methoxy-  
                                            2,4,12,16,18,20,22-heptamethyl-8-[N-(4-methyl-1- 
                                            piperazinyl)formimidoyl]-2,7-
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                                           (epoxypentadeca[1,11,13]trienimino)naphtho[2,1-b]furan       
                                           -1,11-(2H)-dione 21-acetate [13292-46-1].
Physical and Chemical Properties
Appearance:                           orange-red powder 
Melting point:                        183-188°C
Solubility:                              Soluble in dilute acid solutions, slightly soluble in water 
Interactions: 
1. Antacids containing aluminium hydroxide reduces the bioavailability of rifampicin
2. Food lowers peak blood levels because of interference with absorption of rifampicin. 
3. Para-amino salicylic acid granules may delay rifampicin absorption. These two drugs
should be given 8 to 12 hours apart.
4. Isoniazid and rifampicin interaction has led to hepatotoxicity.  
5. Alcohol intake with rifampicin increases the risk for hepatotoxicity. 
6. Rifampicin  induces  microsomal  enzymes  of  the  liver  and  therefore  accelerates
metabolism of some drugs, e.g.  beta blockers, oral contraceptive pills etc.         
7. When rifampicin and oral contraceptives are used concomitantly, there is decreased
effectiveness of oral contraceptives. It was reported that rifampicin may be the cause
of some menstrual disorders when used with oral contraceptive pills.
8. Rifampicin can lower the plasma calciferol (Vitamin D) level because of induction of
enzyme activity.
9. Barbiturates and salicylates decrease the activity of rifampicin. 
 
Rifampicin :  Mechanism of Action and Resistance47
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Rifampin specifically  inhibits  bacterial  RNA polymerase,  the  enzyme responsible  for
DNA transcription, by forming a stable drug-enzyme complex with a binding constant of
10-9  M  at 37oC.  Various steps involved in transcription of bacteria are inhibited when
rifampin  interferes  with  RNA  polymerase.  The  various  steps  in  the  process  of
transcription of DNA to RNA are (1) binding of the enzyme to DNA; (2) binding of the
first  nucleoside tri-phosphate to the enzyme-DNA complex; (3) formation of the first
phosphodiester bond, leading to a dinucleotide (chain initiation); (4) assembly of more
nucleotides  to  form  a  polyribonucleotide  (chain  elongation);  and  (5)  release  of  the
completed RNA chain from the template (chain termination). More specifically,  the β
subunit  of  this  complex  enzyme  is  the  site  of  action  of  drug.  The  corresponding
mammalian enzymes are not affected by rifampin.
Bacterial  resistance  to  rifampin  is  caused  by  mutations  leading  to  a  change  in  the
structure of the  β  subunit of RNA polymerase. Such resistance is not an all-or nothing
phenomenon;  rather,  a  large  number  of  RNA  polymerases  with  various  degrees  of
sensitivity  to  rifampin  have  been  found.  No strict  correlation  exists  between  enzyme
sensitivity and MIC values, since inhibition of RNA synthesis does not always show up
to the same extent in the two different test systems used for the determination of these
values.
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Mechanism of action of Rifampicin on Mycobacterium tuberculosis  (Figure 2)
Formulations of rifampicin in market
Monocomponent products
           Rifampicin capsules of 150 mg, 300 mg, 450 mg, 600 mg           
 
Combination Products 
           Dipicin           Isoniazid 150 mg, Rifampicin 300 mg                  
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           Pyrina            Isoniazid 150 mg, Rifampicin 150 mg, 
                                  Pyrazinamide 500 mg
           Rambutol     Isoniazid 200 mg, Ethambutol HCl 400 mg,
                            Rifampicin 300 mg, Pyridoxine 25 mg
           Rimactazid   Isoniazid 100 mg Rifampicin 150 
                            Isoniazid 200 mg Rifampicin 225 
                            Isoniazid 150 mg Rifampicin 300
Routes of entry
Oral: This is the common route of entry.
Inhalation: Not applicable.
Dermal: Not applicable
Eye: Use for ocular chlamydial infection treatment 
Parenteral: Rifampicin may be given intravenously.
Pharmacokinetics:-
 Absorption: 
 Rifampicin  is  readily  absorbed  from the  gastrointestinal  tract  (90%).   Peak  plasma
concentration occurs at 1.5 to 4 hours after an oral  dose.   After  a 450 mg oral  dose,
plasma levels reach 6 to 9 µg/mL while a 600 mg dose on an empty stomach yields 4 to
32 µg/mL (mean 7 µg/mL).    
Distribution:          
It  is widely distributed in body tissues and fluids. 89% of rifampicin in circulation is
bound to plasma proteins. It is lipid soluble. When the meninges are inflamed, rifampicin
enters  the  cerebrospinal  fluid  (4.0  µg/mL  after  a  600  mg  oral  dose).  It  reaches  at
therapeutic levels in the lungs, bronchial secretions, pleural fluid, other cavity fluid, liver,
bile, and urine. Rifampicin has a high degree of placental transfer with a fetal to maternal
serum level  ratio  of  0.3.   It  is  distributed  into breastmilk.45.  The apparent  volume of
distribution (VD) is 0.93 to 1.6 L/kg.
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Biological half-life by route of exposure: 
           T  1/2 = three hours range (2 to 5 hours).  
Metabolism: 
Approximately 85% of rifampicin is metabolized by the liver microsomal enzymes to its
main  and  active  metabolite-deacetylrifampicin.  Rifampicin  undergoes  enterohepatic
recirculation  but  not  the  deacetylated  form.  Rifampicin  increases  its  own  rate  of
metabolism.  Rifampicin  may also  be  inactivated  in  other  parts  of  the  body.  Formyl
rifampicin is a urinary metabolite that spontaneously forms in the urine. 
Elimination: 
Rifampicin metabolite deacetylrifampicin is excreted in the bile and also in the urine.
Approximately 50% of the rifampicin dose is eliminated within 24 hours and 6 to 30% of
the drug is excreted unchanged in the urine, while 15% is excreted as active metabolite.
Approximately 43 to 60% of oral dose is excreted in the faeces.
Intrinsic total body clearance is 3.5 (+/- 1.6) mL/min/kg, reduced in kidney failure. Renal
clearance is 8.7 mL/min/kg. Rifampicin is excreted in breast milk (1 to 3 µg/ml). 
Uses
 The  primary  indications  for  rifampicin  are  for  treatment  of  tuberculosis
(pulmonary and extra pulmonary lesions) and for leprosy.
 It has some anti chlamydial activity and in vitro activity against some viruses
(pox viruses and adenoviruses. 
 It has recently been used for brucellosis.
Adverse Effects 
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 Severe gastrointestinal side-effects (e.g.pseudomembranouscolitis).
 Hypersensitivity,  shock,  shortness  of  breath,  acute  hemolytic  anemia,  renal
failure (nephrotoxicity).
 The other  adverse  effects  are  staining of  body fluids,  rash,  chills  and  fever,
nausea and vomiting, arthralgia, diarrhea, and peripheral neuritis. 
 Ocular  side  effects  as  a  consequent  to  rifampicin  use  occur  in  5  to  15% of
patients.
 Angioneurotic edema, urticaria, purpura, Stevens-Johnson syndrome, exfoliative
dermatitis or pemphigoid lesions have been reported. 
 Local  ophthalmic  use  of  rifampicin  has  caused  irritation  of  the  eyes  which
manifests  transiently  as  lacrimation,  hyperemia,  edema  and  ocular  pain  in
Special risks 
Toxicity
 Thrombocytopenia
 Hemolysis 
 Renal failure.
 Flu-like syndrome
                                    
4.2 ASCORBIC ACID
Category                   :   Water soluble vitamin
Empirical formula  :    C6H8O6
Structure           :
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Chemical name :   L-ascorbic acid
Molecular weight :   176.1
Melting point :   about 190°C (with decomposition)
Colour :   white to slightly yellowish crystalline powder
Taste :   slight acidic taste. 
Solubility :  freely soluble in water; sparingly soluble in alcohol; insoluble     
                                         in chloroform, in ether, and in benzene.
Dosage and Administration:-
Ascorbic acid (vitamin c) is usually administered orally. When oral administration is not
feasible or when malabsorption is suspected, the drug may be administered IM, IV, or
subcutaneously.  When given parenterally,  utilization of  the vitamin reportedly is  best
after IM administration and that is the preferred parenteral route.The average protective
dose of vitamin C for adults is 70 to 150 mg daily. In the presence of scurvy, doses of
300 mg to 1 g daily are recommended. However, as much as 6 g has been administered
parenterally to normal adults without evidence of toxicity.
Daily intake of dietary vitamin C (according to U.S. recommended dietary allowances),
are listed below. 
Pediatric
• Birth - 6 months: 40 mg
• Infants 6 - 12 months: 50 mg
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• Children 1 - 3 years: 15 mg
• Children 4 - 8 years: 25 mg
• Children 9 - 13 years: 45 mg
• Adolescent girls 14 - 18 years: 65 mg
• Adolescent boys 14 - 18 years: 75 mg
Adult
• Men over 18 years: 90 mg
• Women over 18 years: 75 mg
• Breastfeeding women: 120 mg
Because smoking depletes vitamin C, people who smoke generally need an additional 35
mg per day.
The dose recommended to prevent or treat many of the conditions mentioned in the Uses
section is often 500 - 1,000 mg per day.
Pharmacokinetics:-
Absorption, transport, and disposal
Ascorbic acid  is  absorbed in the body by both active transport  and simple diffusion.
Sodium-Dependent Active Transport—Sodium-Ascorbate Co-Transporters (SVCTs) and
Hexose transporters (GLUTs)—are the two transporters required for absorption. SVCTs
appear to be the predominant system for vitamin C transport in the body.
With regular intake the absorption rate varies between 70 to 95%. However, the degree of
absorption  decreases  as  intake  increases.  At  high  intake  (12g),  fractional  human
absorption of ascorbic acid may be as low as 16%; at low intake (<20 mg) the absorption
rate  can reach  up to 98%.Although the body's  maximal  store of  vitamin C is  largely
determined by the renal threshold for blood, there are many tissues that maintain vitamin
C concentrations far higher than in blood. Biological tissues that accumulate over 100
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times the level in blood plasma of vitamin C are the adrenal glands, pituitary, thymus,
corpus luteum, and retina. Those with 10 to 50 times the concentration present in blood
plasma  include  the  brain,  spleen,  lung,  testicle,  lymph  nodes,  liver,  thyroid,  small
intestinal mucosa, leukocytes, pancreas, kidney and salivary glands.
Ascorbic acid  can be oxidized (broken down)  in  the human body by the enzyme L-
ascorbate oxidase. Ascorbate that is not directly excreted in the urine as a result of body
saturation  or  destroyed  in  other  body  metabolism  is  oxidized  by  this  enzyme  and
removed.
Mechanism of Antioxidants
Ascorbic acid is a mild reducing agent. For this reason, it degrades upon exposure to
oxygen,  especially in the presence of metal ions and light. It  can be oxidized by one
electron to a radical state or doubly oxidized to the stable form called dehydroascorbic
acid.
Ascorbate usually acts as an antioxidant. Typically it reacts with oxidants such reactive
oxygen  species,  such  as  the  hydroxyl  radical  formed  from  hydrogen  peroxide.  Such
radicals are damaging to animals and plants at the molecular level due to their possible
interaction with nucleic acids, proteins, and lipids. Sometimes these radicals initiate chain
reactions.  Ascorbate  can  terminate  these  chain  radical  reactions  by  electron  transfer.
Ascorbic acid is special because it can transfer a single electron, owing to the stability of
its own radical ion called "semidehydroascorbate". dehydroascorbate. 
The net reaction is:
                           RO• + C6H7O6− → ROH + C6H6O6-•.
The  oxidized  forms  of  ascorbate  are  relatively  unreactive,  and  do  not  cause  cellular
damage.
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However,  being a good electron donor, excess ascorbate in the presence of free metal
ions  can  not  only  promote,  but  also  initiate  free  radical  reactions,  thus  making  it  a
potentially dangerous pro-oxidative compound in certain metabolic contexts.
Functions
 Converts Folic Acid into active form Folinic Acid
 Essential for the formation of intercellular material, bone and teeth
 Essential for the absorption of iron
 Fights bacterial and viral  infections Antioxidant which helps defend cells from
the effects of smoke, pollution and other highly reactive substances called free
radicals
 Controls blood cholesterol levels
 Maintains healthy reproductive organs
 May help protect against certain cancers, cataracts and heart disease
 Necessary in production of red blood cells
 Prevents allergic reactions (antihistamine activity)
 Prevents hemorrhaging
Precautions:
Vitamin C supplements have a diuretic  effect,  so  should drink plenty of  fluids when
taking them.
Most commercial vitamin C is made from corn. People sensitive to corn should look for
alternative sources, such as sago palm.
Vitamin  C  increases  the  amount  of  iron  absorbed  from  foods.  People  with
hemochromatosis (an inherited condition where too much iron builds up in the body)
should not take vitamin C supplements.
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While vitamin C is generally considered safe because your body gets rid of what it does
not use, in high doses (more than 2,000 mg daily) it can cause diarrhea, gas, or stomach
upset. If you experience these side effects, lower the dose of vitamin C.
People with kidney problems should talk to their doctor before taking vitamin C.
People who smoke or use nicotine patches may need more vitamin C because nicotine
decreases the effectiveness of vitamin C in the body.
Infants born to mothers taking 6,000 mg or more of vitamin C may develop rebound
scurvy because their intake of vitamin C drops after birth. If  you are pregnant, talk to
your doctor before taking more than 1,000 mg of vitamin C.
Possible Interactions:
 Aspirin and nonsteroidal anti-inflammatory drugs (NSAIDs) -- Both aspirin
and NSAIDs can lower the amount of vitamin C in the body because they cause
more of the vitamin to be lost in urine. In addition, high doses of vitamin C can
cause more of these drugs to stay in the body, raising the levels in your blood.
Some very  early  research  suggests  that  vitamin  C  might  help  protect  against
stomach upset that aspirin and NSAIDs can cause.
 Acetaminophen (Tylenol) -- High doses of vitamin C may lower the amount of
acetaminophen passed in urine, which could cause the levels of this drug in your
blood to rise.
 Barbiturates -- Barbiturates may decrease the effects of vitamin C. These drugs
include  Phenobarbital  (Luminal),  pentobarbital  (Nembutal),  and  seconobarbital
(Seconal).
 Chemotherapy drugs --  As an antioxidant,  vitamin C may interfere with  the
effects of some drugs taken for chemotherapy
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 Nitrate medications for heart  disease --  The combination of vitamin C with
nitroglycerin,  isosorbide  dinitrate  (Isordil),  or  isosorbide  mononitrate  (Ismo)
reduces the body's tendency to build up a tolerance to these medications so that
they no longer work
 Oral contraceptives (birth control pills) and hormone replacement therapy
(HRT) – Oral estrogens can decrease the effects of vitamin C in the body.
 Protease inhibitors --  Vitamin C appears  to slightly lower levels of indinavir
(Crixivan), a medication used to treat HIV and AIDS.
 Tetracycline -- Taking vitamin C with the antibiotic tetracycline may increase the
levels of this medication;  it  may also decrease the effects  of vitamin C in the
body.  Other  antibiotics in the same family include minocycline (Minocin)  and
doxycycline (Vibramycin). 48
      
Toxicity 
 Unpleasant diarrhea
 Gastrointestinal disturbances
 Hyperoxaluria
 Hemolysis
Uses
 Treatment of Scurvy 
  Stabilizes  food and plasma
 Good antioxidant
 Treating lead, mercury and cadmium poisoning.
 Reduces gastric cancer 
 Bleeding gums
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                          5. POLYMER PROFILE
Name of the polymer : - PLGA or poly (lactic-co-glycolic acid)
Structure
Structure of poly(lactic-co-glycolic acid). x= number of units of lactic acid; y= number of
units of glycolic acid.
Typical properties
 PLGA or poly (lactic-co-glycolic acid) is a copolymer which is used in a host of Food
and  Drug  Administration  (FDA)  approved  therapeutic  devices,  owing  to  its
biodegradability and biocompatibility. Depending on the ratio of lactide to glycolide used
for  the  polymerization,  different  forms  of  PLGA  can  be  obtained.  All  PLGAs  are
amorphous rather than crystalline and show a glass transition temperature in the range of
40-60  °C.  Unlike  the  homopolymers  of  lactic  acid  (polylactide)  and  glycolic  acid
(polyglycolide) which show poor solubilities, PLGA can be dissolved by a wide range of
common  solvents,  including  chlorinated  solvents,  tetrahydrofuran,  acetone  or  ethyl
acetate.
The  mechanical  strength,  swelling  behavior,  capacity  to  undergo  hydrolysis  and,
subsequently,  the biodegradation rate are directly influenced by the crystallinity of the
PLGA polymer. The resultant crystallinity of the PLGA co-polymer is dependent on the
type and the molar ratio of the individual monomer components (lactide and glycolide) in
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the copolymer chain. PLGA polymers containing a 50: 50 ratio of lactic and glycolic
acids are hydrolyzed much faster than those containing a higher proportionof either
of the two monomers. 
PGA is highly crystalline because it lacks the methyl side groups of the PLA. Lactic acid
is more hydrophobic than glycolic acid and, therefore, lactide-rich PLGA co-polymers
are less hydrophilic, absorb less water and, subsequently, degrade more slowly.
It  has a glass transition temperature (Tg) of 45°C and an inherent viscosity of 0.5-0.8
mPa. The Tgs of the PLGA co-polymers are above the physiological temperature of 37°C
and  hence  they  are  normally  glassy  in  nature.  Thus,  they  have  a  fairly  rigid  chain
structure,  which  gives  them  significant  mechanical  strength  to  be  formulated  as  a
degradable device. It has been reported that the Tgs of PLGA decrease with the decrease
of lactide content in the co-polymer composition with decreasing M.W. 
Biodegradation of PLGA 
In both in vitro and in vivo, the PLGA co-polymer undergoes degradation in an aqueous
environment (hydrolytic degradation or biodegradation) through cleavage of its backbone
ester  linkages.  The  polymer  chains  undergo  bulk  degradation  and  the  degradation
generally occurs at a uniform rate throughout the PLGA matrix. It has been recorded that
the  PLGA  biodegradation  occurs  through  random  hydrolytic  chain  scissions  of  the
swollen polymer.  The carboxylic  end groups present  in the PLGA chains increase in
number during the biodegradation process as the individual polymer chains are cleaved.
These are known to catalyze the biodegradation process. It  has also been reported that
large fragments are degraded faster internally and amorphous regions degrade faster than
crystalline regions. The biodegradation rates of the PLGA co-polymers are dependent on
the molar ratio of the lactic and glycolic acids in the polymer chain, M.W. of the polymer
and the degree of crystallinity 
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Applications
The  possibility  to  tailor  the  polymer  degradation  time  by  altering  the  ratio  of  the
monomers used during synthesis has made PLGA a common choice in the production of
a  variety  of  biomedical  devices  such as:  grafts,  sutures,  implants,  prosthetic  devices,
micro and nanoparticles. They are also easy to formulate into various delivery systems
for  carrying  a variety of  drug classes,  such as vaccines,  peptides,  proteins and micro
molecules, which have been approved by the Food and Drug Administration for drug
delivery use. 
It has been used successfully in delivery of Amoxicillin in treating listeriosis (treatment
of  Listeria  monocytogenes  infection).As  an  example,  a  commercially  available  drug
delivery device using PLGA is Lupron DepotⓇ for the treatment of advanced prostate
cancer.49
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6. AIM AND OBJECTIVE
Rifampicin  when  administered  alone  or  in  combination  with  Isoniazid,
Pyrazinamide  and  Ethambutol  degrades  in  the  stomach  and  results  in  poor
bioavailability  which  makes  difficulties  in  effectively  controlling  tuberculosis.
Development of any method that can stabilize rifampicin against degradation in
the gastric environment will be therapeutically beneficial.
           Aim and objective of the present study is:-
1)  To  prepare  rifampicin  –  PLGA  nanoparticles  using  ascorbic  acid  as  an
antioxidant to improve the   stability of rifampicin.
2) Evaluation of the prepared nanoparticles.
 Shape  and  Surface  morphology  of  the  prepared  nanoparticles
(SEM)
 Particle size and size distribution 
 Polydispersity Index
 Zeta potential study
 Statistical analysis
3)  To carry out the  in-vitro dissolution study of the prepared  nanoparticles  to
observe the degradation of rifampicin alone and with ascorbic acid of different
concentrations  in   pH  1.2  medium  to  investigate  whether  ascorbic  acid  can
improve the stability of rifampicin in gastric  pH condition and so improve the
bioavailability of rifampicin.
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                                                               7.PLAN  OF WORK
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AND
EQUIPMENTS 
8. MATERIALS AND EQUIPMENTS
8.1. Materials used
Sl.No:                           Materials                                   Manufactured/ Supplied by
  1.                            Rifampicin                                Astha Laboratories,India
  2.                            Ascorbic acid                           Qualigens Fine chemicals.Mumbai
  3.                            P LGA                                      Boehringer Ingelheim Pharma
  4.                            Dichloromethane                     Nice chemicals Pvt.Ltd.Mumbai
  5.                            Polyvinyl alcohol                     Molychem.India
                                
8.2. Equipments used
Sl.No:                   Equipments                                       Manufactured/Supplied by
  1.                        Magnetic stirrer                                   Elektrocrafts,Mumbai
  2.                        Ultrasonicator                                      Bandelin Sonoplus model HD
  3 .                       UV/Visible spectrophotometer            Perkin Elmer Lambda-25
  4.                        Single pan Digital Balance                  Shimadzu ELB 300
  5.                        Dissolution test apparatus-USP           Veego apparatus,Chennai
  6.                        Scanning Electron Microscope            Philips XL 30,Eindhoven
  7.                        Laser Particle size analyzer                 Malvern Instruments UK
  8.                        Zetasizer                                              Malvern Instruments UK 
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9.   METHODOLOGY
9.1. PREPARATION OF NANOPARTICLES
Rifampicin  and  ascorbic  acid  loaded  PLGA  nanoparticles  were  fabricated  by  an
Emulsification/solvent  evaporation  method,  which  involved  the  formation  of  stable
emulsion  and  evaporation  of  organic  solvent  by  continuous  stirring.  The  study  was
carried out by preparing four types of formulations.
        Formulation 1 (F1) is rifampicin alone loaded PLGA  nanoparticles, formulation II (F2)is
rifampicin  –ascorbic  acid(1:1)  loaded  PLGA   nanoparticles,  formulation  III  (F3)is
rifampicin  -ascorbic  acid  (1:2)  nanoparticles  and  formulation  IV  (F4)is  rifampicin  –
ascorbic acid (1:3) loaded nanoparticles. In all the cases, drug: polymer ratio was taken as
1:1 and ascorbic acid was taken in three different ratios as shown in Table 1
                      
Procedure:-
Drug loaded PLGA nanoparticles were prepared by a multistep emulsion procedure.50
mg of rifampicin and required quantities of ascorbic acid were accurately weighed and
added to  10ml of  dichloromethane containing the polymer  [drug :  polymer  ratio was
taken as (1:1)]. Distilled water was emulsified in the DCM containing drug and polymer
to form w/o primary emulsion.  It  was then emulsified by sonication for  15 minutes.
Primary emulsion was then poured into 8ml of 1%w/v  aqueous Poly Vinyl  Alcohol
solution and stirred using a magnetic stirrer to form the second w/o/w multiple emulsion.
The latter was then stirred continuously overnight for the complete removal DCM. The
nanoparticles were then recovered by centrifugation (9000 -10,000 rpm for 15 minutes),
washed thrice with distilled water and vaccum dried.37
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Table 1
FORMULATION CODE INGREDIENTS
                      F0
F1
F2
F3
F4
       PURE RIFAMPICIN 
     RIFAMPICIN+PLGA(1:1)
 RIF+PLGA+ASC(1:1:1)
 RIF+PLGA+ASC(1:1:2)
 RIF+PLGA+ASC(1:1:3)
9.2. EVALUATION OF THE PREPARED NANOPARTICLES
Characterization  of  the  prepared  nanoparticles  was  then  carried  out.  It  includes
determination  of  particle  size,  size  distribution,  shape,  surface  morphology,  Poly
dispersity Index and zeta potential. Scanning electron microscopy was used to determine
the  shape  and  surface  morphology  of  the  nanoparticles.  Average  particle  size  and
polydispersity index of nanoparticles were measured by Laser light scattering method.
Zeta potential of the nanoparticles was determined using a zetasizer.
Shape and surface morphology of nanoparticles 1
The morphology of Rifampicin –ascorbic acid loaded PLGA nanoparticles were analyzed
using a scanning electron microscope. Samples were prepared from dilutions in distilled
water of particle suspensions and dropped onto stubs using double sided sticking tape.
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After  air  drying,  particle  were  coated  with  a  thin  layer  of  platinum  film  and  then
examined by scanning electron microscopy. 
Particle size characterization of the nanoparticles 7
The particle size, size distribution and poly dispersity index of the nanoparticles were
measured by a laser particle size analyzer after suitable dilutions.
Zeta Potential Study 1
The surface charge of nanoparticles was determined by the electrophoretic mobility of
nanoparticles in a U type tube at 25˚C, using a zetasizer .
9.3.    INVITRO  RELEASE  STUDY 5
A solution of 0.1N HCL was placed in the vessel of USP dissolution apparatus type 2
(US Pharmacopoeia XXIII,  1995) with rotating paddle at 100rpm and the temperature
was  maintained  at  37±0.2oc.RIF  loaded  PLGA  nanoparticles  with  ascorbic  acid  of
different ratios were accurately weighed, dissolved in and diluted to 100ml with 0.1N
HCL.  The  resulting  solution  was  transferred  immediately  to  the  dissolution  bath.
Specimens were withdrawn at 15 min, 30min and 60min.An aliquot, 0.5ml, 1ml, 2 ml,
3ml, 4 ml and 5ml were extracted immediately with 100ml of pH 1.2 medium using a
cyclomixer.  Samples  were  analyzed  spectrophotometrically  at  475nm1,7 and  the
percentage degradation was calculated using the given formula2
  
 % Degradation loss    =        Initial concentration - Final concentration      X   100
                                                                Initial Concentration
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9.4. PROCEDURE FOR PREPARATION OF pH 1.2 BUFFER:
Preparation of pH 1.2: 50ml 0f 0.2M KCl is mixed with 85ml of 0.2M HCl and make
up to 200ml with water.
Note: 
0.2M KCl: 14.911gm of KCl was dissolved in H2O and dilute with water and made up to
1000ml.
0.2M HCl: 17ml of HCl was mixed with 1000ml 0f H2O. 50
Preparation of standard stock solution:
100mg Rifampicin PLGA nanoparticles were dissolved in 100ml pH 1.2 solution. From
this required quantities were taken for further dilution process.
Dilution process:                                      
                                                                      ↓
        0.5ml→100ml (5 µg)
                                      1ml → 100ml (10 µg)
        2ml → 100ml (20 µg)
        3ml → 100ml (30 µg)
        4ml → 100ml (40 µg)
        5ml → 100ml (50 µg)
Standard calibration curve for Rifampicin + Ascorbic acid (1:1) nanoparticles at pH
1.2:
100 mg of rifampicin - ascorbic acid nanoparticles (1:1) were accurately weighed and
dissolved in 100ml of pH 1.2 buffer.
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10. RESULTS
10.1. SHAPE AND SURFACE CHARACTERIZATION OF THE PREPARED
NANOPARTICLES [SEM]
Scanning electron micrograph of the prepared Rifampicin - Ascorbic acid loaded PLGA
nanoparticles are shown in Figure 3 
    
SEM images revealed that the nanoparticles were spherical with smooth surface and they
are relatively mono dispersed.
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                                                    Figure - 3
2µm
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10.2. PARTICLE SIZE CHARACTERIZATION OF THE NANOPARTICLES
The mean particle size and polydispersity Index of all the samples were determined 
(Table 2 )     
Table 2
S.NO FORMULATIONS MEAN DIAMETER(nm)±SD PdI
1.
2.
3.
4.
RIFAMPICIN+PLGA(1:1)
RIF+PLGA+ASC(1:1)
RIF+PLGA+ASC(1:2)
RIF+PLGA+ASC(1:3)
375± 20
378 ± 22
374 ± 18
380 ± 23
0.312
0.316
0.308
0.317
Laser particle size analyzer yields the diameter of the bulk population. Particles were in
the size range of 374-380 ± 18-23 (SD) nm. Polydispersity index is a measure of the
distribution of particles in a given polymer sample. It gives the distribution range from
0.000 to 0.500.Polydispersity index greater than 0.5 indicates aggregation of particles.
Here it is in the range of 0.308 - 0.317.
10.3. ZETA POTENTIAL STUDY
Zeta potential is a term related to the stability of samples. For molecules and particles that
are small enough, high zeta potential will confer stability i.e. it resist aggregation. Here
zeta potential of the prepared nanoparticle was found to be -46.6, which would not allow
aggregation.
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10.4. IN-VITRO STABILITY STUDY
Standard curves of rifampicin alone and in combination with ascorbic acid in
different ratios at pH 1.2 buffer (Table 3)
Table -3
Conc.
in µgm
Rif Rif +
PLGA NPs
Rif+asc(1:1)
NPs
Rif+asc(1:2)
NPs
Rif+asc(1:3)
NPs
0 0 0 0 0 0
5 0.082 0.084 0.090 0.052 0.054
10 0.160 0.162 0.140 0.103 0.093
20 0.305 0.320 0.280 0.192 0.181
30 0.456 0.473 0.422 0.280 0.273
40 0.607 0.633 0.561 0.381 0.352
50 0.759 0.801 0.701 0.475 0.446
Figure 4
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Figure 5
     
Figure 6
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Figure 7
                                     
Figure 8
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Invitro Stability study of rifampicin PLGA nanoparticles and rifampicin in
combination with ascorbic acid in different ratios at pH 1.2 buffer (Table 4 - 8)
                              
Pure Rifampicin              (Table 4)
Time
(mins)
Absorbance Concentration % drug release
Mean % drug
release±SDTrial
1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
0 0 0 0 0 0 0 0 0 0 0
15 0.620 0.621 0.619 43.20 43.21 43.19 38.8 38.81 38.79 38.80±0.010 %
30 0.861 0.860 0.859 56.41 56.40 56.39 50.77 50.76 50.75 50.76±0.010 %
60 0.980 0.980 0.981 71.20 71.20 71.21 64.08 64.08 64.09 64.08±0.005 %
P value *0.0197
Figure 9
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RIFAMPICIN + PLGA NANOPARTICLES       (Table  5)
Time
(mins)
Absorbance Concentration % drug release
Mean % drug
release±SDTrial  
1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
0 0 0 0 0 0 0 0 0 0 0
15 0.190
0.20
2
0.20
1
18.1 18.2 18.2
16.3
9
16.42
16.4
2
16.38± 0.07  %
30 0.335
0.33
4
0.33
5
21.90 21.8 21.9
19.7
1
19.70
19.7
1
19.71±0.005 %
60 0.420
0.42
1
0.42
2
27.20 27.20
27.2
1
24.4
8
24.48
24.5
0
24.48 ±0.011 %
P value       *0.0133
Figure 10
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RIFAMPICIN + ASCORBIC ACID (1:1)      Table 6
Time
(min)
Absorbance Concentration % drug release
Mean % drug
release±SDTrial1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
0 0 0 0 0 0 0 0 0 0 0
15 0.410 0.413 0.412 22.5 29.4 30.0 26.46 26.48
26.4
8
 26.46±0.011%
30 0.472 0.471 0.472 34.20 34.11 34.20 30.61 30.59
30.6
1
 30.60±0.010 %
60 0.540 0.542 0.541 39.80 39.82 39.82 35.82 35.83
35.8
3
35.82±0.005 %
Pvalue      **0.0076
Figure 11
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RIFAMPICIN + ASCORBIC ACID (1:2)       Table 7
Time
(mins)
Absorbance Concentration % drug release
Mean % drug
release±SDTrial1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
0 0 0 0 0 0 0 0 0 0 0
15 0.360 0.359 0.361 37.00 36.90 37.10 33.20 33.19 33.21 33.20±0.010%
30 0.391 0.390 0.389 43.21 43.20 43.14 38.81 38.80 38.79 38.80±0.010 %
60 0.442 0.440 0.440 45.73 45.71 45.71 41.15 41.13 41.13 41.13±0.011%
P
value
**0.0039
Figure 12
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RIFAMPICIN + ASCORBIC ACID (1:3)   Table  8
Time
(mins)
Absorbance Concentration % drug release Mean % drug
release±SD
Trial1 Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
Trial
1
Trial
2
Trial
3
0 0 0 0 0 0 0 0 0 0 0
15 0.351 0.349 0.350 44.71 44.69 44.7 40.21 40.19 40.20 40.20±0.010 %
30 0.442 0.440 0.444 49.20 49.00 49.22 44.20 44.19 44.22 44.20±0.015 %
60 0.446 0.445 0.447 49.90 49.89 49.90 44.89 44.88 44.90 44.89±0.010 %
P
value
**0.0011
Figure 13
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% DRUG RELEASE PROFILE OF THE FORMULATIONS
Table 9
Time
(min)
F0 F1 F2 F3 F4
0 0 0 0 0 0
15 38.80±0.010 % 16.38±0.07% 26.46±0.011% 33.20±0.010% 40.20 ±0.010 %
30 50.76±0.010 % 19.71±0.005% 30.60±0.010% 38.80±0.010% 44.20 ±0.015%
60 64.08± 0.005% 24.48±0.011 % 35.82±0.005% 41.13±0.011% 44.89 ±0.010%
% DRUG RELEASE PROFILE OF THE FORMULATIONS Figure 14
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Statistical Analysis of all the formulations 
One way Analysis of Variance (ANOVA) : Tukey-Kramer Multiple Comparisons   
Test 
Table 10 
Comparison P  value  
       F0 vs   F1
       F0 vs F2
       F0 vs F3
       F0 vs F4
       F1 vs F2
**  P<0.01  
*  P<0.05
ns  P>0.05
ns  P>0.05
ns  P>0.05
60
       F1 vs F3
       F1 vs F4  
       F2 vs F3
       F2 vs F4
       F3 vs F4 
ns  P>0.05
                  *  P<0.05
ns  P>0.05
  ns  P>0.05
  ns  P>0.05
       P value                 **   0.0020 
   *       considered significant
   **      considered very significant
  
Statistical Analysis of nanoparticles
One way Analysis of Variance (ANOVA):  Tukey-Kramer Multiple Comparisons         Test
Table 11
Comparison P  value  
       F1 vs   F2
      F1 vs F3
       F1 vs F4
       F2 vs F3
*  P<0.05   
**  P<0.01
*** P<0.001
ns  P>0.05
61
       F2 vs F4
       F3 vs F4
*   P<0.05
ns  P>0.05
Overall P value *  * *0.0005
              
 
COMPARITIVE % DRUG DEGRADATION PROFILE
Table 12
Formulation
Code
% drug degradation
F0 64.81 %
F1 49.77 %
F2 40.17 %
F3 23.54 %
F4 11.61 %
P value *  0.0156
           
       
% DRUG DEGRADATION PROFILE OF F0 TO F4
Figure 15
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11. DISCUSSION
Rifampicin  is  a  first  line  anti-tubercular  drug,  administered  orally  in  fixed  dose
combination with Isoniazid,  Pyrazinamide and Ethambutol in order  to overcome drug
resistance to tuberculosis arising from administration of these drugs separately. However
bioavailability of rifampicin is reduced owing to degradation of the drug in the stomach.
Rifampicin degrades in acidic condition of the stomach and the degradation of rifampicin
is pH dependent.51 One report says that the problem of poor absorption of rifampicin from
combination products is perhaps due to increased decomposition in stomach conditions
and the decomposition of rifampicin is enhanced in the presence of INH.52
Rifampicin is well absorbed in the pH range of 1-2 even though it undergoes degradation
in the acidic  medium. Rifampicin hydrolyses  to  3  formyl  rifampicin  SV (3-FRSV)in
acidic condition  and it  undergoes  air oxidation in alkaline medium to form in active
quinone  derivative  rifampicin  quinine.53 It  shows  high  antimicrobial  activity  but  is
inactive  in  in-vivo (USP  DI,1996).  Therefore  formation  of  3-FRSV  in  the  acidic
environment of stomach can be an important factor affecting bioavailability of rifampicin
and cannot be overlooked.
Development of any method that can prevent or minimize degradation of rifampicin in
the stomach either as a single drug or in combination of other anti tubercular drug is
therapeutically beneficial and can achieve effective control of tuberculosis with improved
bioavailability of rifampicin.
Previous study shows that the degradation of rifampicin due to oxidative side reaction
was prevented by the addition of  ascorbic acid  to the reaction media.54Another  study
reveals  the  protective  effect  of  adding ascorbic  acid  on the stability of  rifampicin in
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plasma and that the degradation can be effectively prevented by adding ascorbic acid thus
prolonging stability for 12 hours.46
Based on the above factors the present study  aimed  to prepare and evaluate  Rifampicin
loaded  PLGA nanoparticles  and an attempt was made to investigate the influence of
ascorbic acid as an antioxidant on stabilizing rifampicin in the gastric environment by
invitro study  in pH 1.2 medium simulating the condition in stomach.
Evaluations of the prepared nanoparticles were then carried out by different  methods.
Shape and Surface characterization of the nanoparticles were done by Scanning Electron
microscopy and the SEM images  revealed  that  the nanoparticles  were  spherical  with
smooth surface and the nanoparticles were found to be relatively mono dispersed. Laser
particle  size analyzer  yields  the diameter  of  the bulk population and a polydispersity
index gives the distribution range from 0.000 to 0.500. Polydispersity index is a measure
of the distribution of particles in a given polymer sample. PdI greater than 0.5 indicates
aggregation of particles. Here the polydispersity indexes of the nanoparticles were in the
range of 0.308-0.317.
Particles were in the size range of 374 - 380 ± 18 - 23 (SD) nm. Particle size of the
nanoparticle  can  be  affected  by  processing  parameters  such  as  drug/polymer  ratio,
concentration of surfactant and stirring speed. Since in the present study these parameters
were  maintained  constant,  their  influence  on  the  mean  particle  size  of  nanoparticles
cannot be ascertained.
Zeta potential is a term related to the stability of samples. For molecules and particles that
are small enough, high zeta potential will confer stability i.e. it resist aggregation. When
zeta potential  is  low,  attraction  exceeds  repulsion.  Therefore  particles  with  high  zeta
potential (-ve or + ve) are electrically stabilized. Generally particle aggregation is less
likely to occur for charged particles (high zeta potential) due to electric repulsion. Lower
zeta potential  facilitates aggregation.  Here zeta potential  of the prepared nanoparticles
was found to be -46.6, which would not allow aggregation.
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The invitro dissolution study was conducted for 1 hour. It was carried out using the five
formulations.  First  formulation is  pure Rifampicin.  Second is rifampicin alone loaded
PLGA nanoparticles and in the next three formulations ratio of rifampicin and PLGA
were same where as the concentration of ascorbic acid was increased. The dissolution
study was carried out in pH 1.2 solutions to simulate the acidic gastric  condition. At
specific time intervals samples were withdrawn and analyzed by U.V spectrophotometer.
Percentage  release  of  drug  from the  nanoparticles  at  15min,  30min and  60min  were
determined and the percentage degradation of the drug was also calculated.
The results of the invitro drug dissolution study indicates that the % drug release of the
formulation F0,  F1,  F2,  F3 and  F4 at  60 minutes  was found to  be 64.08%, 24.48%,
35.82%, 41.13% and 44.89 % respectively and the percentage drug degradation of the
formulation F0, F1, F2, F3 and F4 was found to be 64.81%, 49.77 %, 40.17 %, 23.54%
and 11.61 % respectively.
From the data obtained it is understood that ascorbic acid minimized the degradation of
rifampicin and the degradation was further reduced when the concentration of ascorbic
acid was increased. Statistical analysis of the % drug degradation profile was done and it
was  found  that  there  is  a  statistically  significant  change  (statistically  significant;  *P
0.0156)  in  the  percentage  degradation  as  the  concentration  of  ascorbic  acid  was
increased. It  can be hypothesized that ascorbic acid being an antioxidant prevents the
oxidative side reactions of rifampicin in the gastric pH and minimized the
degradation of rifampicin.
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CONCLUSION 
            12. SUMMARY & CONCLUSION
The results of the study demonstrate that ascorbic acid can minimize the degradation of
rifampicin in gastric pH condition and thus improves the stability and therapeutic efficacy
of rifampicin. The study also concluded that there is statistically a significant change in
the percentage  drug degradation  profile  when  the concentration  of  ascorbic  acid  was
increased. Further invivo studies are recommended to address the therapeutic efficacy of
rifampicin –ascorbic acid loaded PLGA nanoparticles
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